The sequential occurrence of vital mutations in a liver transplant recipient re-infected with hepatitis B: Hepatitis B immune globulin escape, famciclovir non-response, followed by lamivudine resistance resulting in graft loss

Journal of Hepatology

Volumn 29, Issue 4, 1998, Pages 669-675

  De Man, Robert A ^a   Bartholomeusz, Angeline I ^b   Niesters, Hubert G M ^a   Zondervan, Pieter E ^a   Locarnini, Stephen A ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

Antiviral therapy; Famciclovir; Hepatitis B; Hepatitis B immune globulin; Lamivudine; Liver transplantation; Viral resistance

Indexed keywords

FAMCICLOVIR; HEPATITIS B ANTIBODY; LAMIVUDINE; PENCICLOVIR; VIRUS DNA; 2 AMINOPURINE; ANTIVIRUS AGENT; DNA DIRECTED DNA POLYMERASE; DRUG DERIVATIVE; HEPATITIS B HYPERIMMUNE GLOBULIN; IMMUNOGLOBULIN; VIRUS PROTEIN;

ADULT; ARTICLE; CASE REPORT; CHRONIC ACTIVE HEPATITIS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER TRANSPLANTATION; MALE; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; REINFECTION; SEQUENCE ANALYSIS; STRUCTURAL GENE; TREATMENT OUTCOME; VIRUS MUTATION; VIRUS RESISTANCE; AMINO ACID SEQUENCE; CHEMISTRY; DRUG RESISTANCE; LIVER; MIDDLE AGED; MOLECULAR GENETICS; MUTATION; PASSIVE IMMUNIZATION; PATHOLOGY; RECURRENT DISEASE;

2-AMINOPURINE; AMINO ACID SEQUENCE; ANTIVIRAL AGENTS; DNA, VIRAL; DNA-DIRECTED DNA POLYMERASE; DRUG RESISTANCE; HEPATITIS B; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULINS; LAMIVUDINE; LIVER; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; RECURRENCE; VIRAL PROTEINS;

EID: 0032173354     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(98)80164-5     Document Type: Article

References (18)

1. 1. Samuel D, Bismuth A, Mathieu D, Arulnaden JL, Reynes M, Benhamou JP, et al. Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients. Lancet 1991; 337: 813-5.
2. 2. Muller R, Samuel D, Fassati L, Benhamou J, Bismuth H, Alexander G. Eurohep consensus report on the management of liver transplantation for hepatitis B virus infection. J Hepatol 1994; 21: 1140-3.
3. 3. Fang J, Tung F, Davis G, Dolson D, Van Thiel D, Lau J. Fibrosing cholestatic hepatitis in a transplant recipient with hepatitis B pre-core mutant. Gastroenterology 1993; 105: 901-4.
4. 4. Angus P, Locarnini S, McCaughan G, Jones R, McMillan J, Bowden D. Hepatitis B virus pre-core mutant infection in association with severe recurrent disease after liver transplantation. Hepatology 1995; 21: 14-8.
5. 5. Angus P, Richards M, Bowden S, Ireton J, Sinclair R, Jones R, et al. Combination antiviral therapy controls severe postliver transplant recurrence of hepatitis B virus infection. J Gastroenterol Hepatol 1993; 8: 353-7.
6. 6. Quint WG, Heijtink RA, Schirm J, Gehrlich WH, Niesters HGM. Reliability of methods for hepatitis B virus DNA detection. J Clin Microbiol 1995; 33: 225-8.
7. 7. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-5.
8. 8. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994; 19: 1513-20.
9. 9. Snover DC, Freese DK, Sharp HL, Bloomer JR, Najarian JS, Ascher NL. Liver allograft rejection. An analysis of the use of biopsy in determining outcome of rejection. Am J Surg Pathol 1987; 11: 1-10.
10. 10. Perry CM, Wagenstaff AJ. Famciclovir. A review of its pharmacological properties and therapeutic efficacy in herpes virus infections. Drugs 1995; 50: 396-415.
11. 11. Aye TT, Bartholomeusz A, Shaw T, Bowden S, Breschkin A, McMillan J, et al. Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation. J Hepatol 1997; 26: 1148-53.
12. 12. Poch O, Sauvaget I, Delarue M, Tordo N. Identification of four conserved motifs among the RNA dependent polymerase encoding elements. EMBO J 1989; 8: 3867-74.
13. 13. Bartholomeusz A, Locarnini S. Mutations in the hepatitis B virus polymerase gene that are associated with resistance to famciclovir and lamivudine. Int Antiviral News 1997; 5: 123-4.
14. 14. Ling R, Mutimer D, Ahmed M, Boxall EH, Ellas E, Dusheiko GM, et al. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996; 24: 711-3.
15. 15. Honkoop P, Niesters HGM, de Man RA, Osterhaus ADME, Schalm SW. Lamivudine resistance in immunocompetent chronic hepatitis B: incidence and patterns. J Hepatol 1997; 26: 1393-5.
16. 16. Tisdale M, Kemp SD, Parry NR, Larder BA. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. PNAS 1993; 90: 5653-6.
17. 17. Colledge D, Locarnini S, Shaw T. Synergistic inhibition of hepadnaviral replication by lamivudine in combination with penciclovir in vitro. Hepatology 1997; 26: 216-25.
18. 18. Fontana RJ, Lok AS. Combination therapy for chronic hepatitis B. Hepatology 1997; 26: 234-7.